glp-1 news november 25 2025 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs As GLP-1 Drugs Go Mainstream,

So far, Phase II and Phase IIb studies of avexitide in PBH have shown a statistically significant reduction in hypoglycemic events characterized by low blood glucose

Expression of Mcl-1 is upregulated in many cancers, and it was seen to be upregulated as a resistance factor to chemotherapies, Keating says

Another report suggests that from 2023 until mid 2024, the monthly volume for the search term copper peptide serum has grown about 68%

Some oral GLP-1 medications have shown strong clinical trial results, but results vary by medication, dose, adherence, side effects, and patient factors

Papaccio F, DArino A, Caputo S, Bellei B

113th PSA Annual Meeting Abstracts